For companies involved in the pharmaceutical sector, particularly those synthesizing complex drugs like Idelalisib, the procurement of high-quality intermediates is a strategic imperative. (S)-2-hydroxybutanoic acid, identified by CAS 3347-90-8, stands out as a critical chiral intermediate. Its enantiomeric purity is directly linked to the therapeutic efficacy and safety profile of the final drug product. Therefore, understanding how to effectively source this compound is paramount for pharmaceutical R&D and manufacturing operations.

When considering where to buy (S)-2-hydroxybutanoic acid, pharmaceutical buyers must prioritize suppliers with a proven track record in producing intermediates that meet stringent quality standards. This involves looking beyond just the chemical name and CAS number to inquire about the manufacturing processes, quality control measures, and analytical capabilities of potential suppliers. A certificate of analysis (CoA) for (S)-2-hydroxybutanoic acid should clearly detail its assay (typically ≥98.0%), enantiomeric excess, and impurity profiles. Without this detailed information, manufacturers risk introducing variability into their synthesis, potentially leading to batch failures or regulatory issues.

The primary application of (S)-2-hydroxybutanoic acid in Idelalisib synthesis highlights the importance of its specific stereochemistry. Idelalisib is a targeted therapy, and its mechanism of action is highly dependent on the correct spatial arrangement of its molecular components. Using a racemic mixture or an intermediate with insufficient enantiomeric purity would result in a final product that is either inactive or has a different, potentially harmful, pharmacological profile. This reinforces the need to partner with an S-2-hydroxybutanoic acid manufacturer that specializes in chiral synthesis and can provide consistent, high-enantiomeric-purity material. The price of (S)-2-hydroxybutanoic acid can vary based on purity and scale, but investing in quality is a crucial risk mitigation strategy.

Beyond Idelalisib, (S)-2-hydroxybutanoic acid may also find use in the synthesis of other pharmaceuticals or fine chemicals where a specific chiral hydroxyl acid moiety is required. As an S-2-hydroxybutanoic acid intermediate, it offers chemists a versatile chiral building block. The physical properties, such as its crystalline powder form and melting point, also play a role in its ease of handling and integration into various reaction conditions. Manufacturers must ensure that packaging, such as 25 kg drums, is suitable for maintaining product integrity during transport and storage.

In conclusion, pharmaceutical buyers seeking to secure a reliable supply of (S)-2-hydroxybutanoic acid must conduct thorough due diligence on potential suppliers. Focusing on guaranteed purity, precise enantiomeric control, robust quality systems, and consistent supply is key. By prioritizing these factors, companies can ensure the success of their Idelalisib synthesis and other downstream applications, ultimately contributing to the delivery of safe and effective medicines to patients.